CMS Finalizes Reimbursement For Exact Sciences’ Colorectal Cancer Test
This article was originally published in The Gray Sheet
The agency affirmed a positive payment rate for Exact Science's Cologuard DNA stool test. The firm says it is beginning to implement its marketing plan targeting docs that more frequently prescribe fecal tests, and patients more broadly on social media.
You may also be interested in...
CMS granted the company a broad-based national coverage policy at breakneck speed and a positive preliminary payment decision to boot for the Cologuard DNA stool test. It is the first national coverage determination resulting from the FDA-CMS parallel review pilot.
CMS opened a national coverage determination for Exact Sciences Cologuard, the first stool-based colorectal cancer screening test on the same day FDA approved the test. This is the first simultaneous approval/coverage determination under FDA and CMS’ joint parallel review program.
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Thirty-eight guidance documents have been posted on the tracker since its last update.